<\/p>\n
Hytrin<\/strong> er en 1 \/ 2 \/ 5 mg Terazosin tablet<\/strong> from AbbVie — a long-acting selective alpha-1 adrenergic receptor antagonist (quinazoline)<\/strong>, der virker p\u00e5 post-synaptic alpha-1 adrenergic receptors on arterial smooth muscle and on prostatic\/bladder-neck smooth muscle<\/strong>. Terazosin was introduced by Abbott (now AbbVie) in 1987 as Hytrin<\/strong> — developed as a longer-acting successor to prazosin, with a 12-hour half-life that permits once-daily dosing. Structurally a close quinazoline analogue of prazosin. Widely used in the 1990s and 2000s for benign prostatic hyperplasia (BPH) and as an add-on antihypertensive; partially displaced by the prostate-selective alpha-1A blockers (tamsulosin, silodosin) for BPH-only use, but retains a strong position where coexisting hypertension makes a non-selective alpha-blocker appropriate. Half-life 12 hours (once-daily dosing appropriate); onset 1-2 hours; peak 1-2 hours; symptomatic BPH benefit typically at 2-4 weeks. Primary indications: benign prostatic hyperplasia, resistant hypertension as add-on agent<\/strong>. Typisk dosering: Hypertension:<\/strong> start 1 mg at bedtime (first-dose phenomenon risk), titrate every 1-2 weeks up to 5-20 mg\/day. The longer half-life vs prazosin makes once-daily dosing practical. Ikke et f\u00f8rstelinje antihypertensivt middel.<\/strong> ALLHAT stopped the doxazosin arm early for excess HF; terazosin is extrapolated to the same class concern. Reserve for fourth\/fifth-line use, especially where BPH coexists. Start altid den f\u00f8rste dosis ved sengetid<\/strong> \u2014 \u201cf\u00f8rste-dosis\u201d-f\u00e6nomenet for\u00e5rsager alvorlig ortostatisk hypotension i de f\u00f8rste timer. Ikke en f\u00f8rstevalgs antihypertensiv (ALLHAT klassebekymringer) \u2014 reserver til fjerde\/femte-linjes brug, is\u00e6r hvor BPH er til stede. For de fleste hypertensionspatienter starter moderne behandling med en ACE-h\u00e6mmer\/ARB, en calciumkanalbloker, et thiazid og spironolakton f\u00f8r man overvejer en alfa-bloker eller centralt virkende middel.<\/p>\n<\/div>\n \ud83d\udce6 Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis din pakke ikke ankommer inden for 20 hverdage, sender vi en erstatning.<\/p>\n Vores generiske medicin kommer fra WHO-GMP certificerede producenter og sendes verdensomsp\u00e6ndende i diskret, neutral emballage \u2014 ingen medicinnavn p\u00e5 pakkens ydre. Kortbetalinger h\u00e5ndteres af en reguleret processor (kontoudtogsbeskrivelser inkluderer en reguleret betalingsprocessor \u2014 aldrig \u201cMedsBase\u201d eller medicinnavn). Crypto og SEPA bankoverf\u00f8rsel accepteres ogs\u00e5. Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy.<\/p>\n Hytrin is an oral 1 \/ 2 \/ 5 mg Terazosin tablet from AbbVie, supplied in 30-180 tablets. Terazosin was introduced by Abbott (now AbbVie) in 1987 as Hytrin<\/strong> — developed as a longer-acting successor to prazosin, with a 12-hour half-life that permits once-daily dosing. Structurally a close quinazoline analogue of prazosin. Widely used in the 1990s and 2000s for benign prostatic hyperplasia (BPH) and as an add-on antihypertensive; partially displaced by the prostate-selective alpha-1A blockers (tamsulosin, silodosin) for BPH-only use, but retains a strong position where coexisting hypertension makes a non-selective alpha-blocker appropriate.<\/p>\n Terazosin acts on post-synaptic alpha-1 adrenergic receptors on arterial smooth muscle and on prostatic\/bladder-neck smooth muscle<\/strong>. De nedstr\u00f8mmende effekter:<\/p>\n Afg\u00f8rende kliniske fors\u00f8gsresultater:<\/strong> HYTRIN Community Assessment Trial (HYCAT, 1996)<\/strong> — terazosin improved IPSS by 37% in 2,084 men with symptomatic BPH over 1 year. VA Cooperative BPH Trial (Lepor, NEJM 1996)<\/strong> — terazosin + finasteride no better than terazosin alone in men with smaller prostates, foreshadowing the MTOPS finding that combination therapy helps larger prostates. ALLHAT doxazosin-arm (2000)<\/strong> — class-level HF signal.<\/p>\n Prim\u00e6r dosis:<\/strong> Hypertension:<\/strong> start 1 mg at bedtime (first-dose phenomenon risk), titrate every 1-2 weeks up to 5-20 mg\/day. The longer half-life vs prazosin makes once-daily dosing practical. Ikke et f\u00f8rstelinje antihypertensivt middel.<\/strong> ALLHAT stopped the doxazosin arm early for excess HF; terazosin is extrapolated to the same class concern. Reserve for fourth\/fifth-line use, especially where BPH coexists.<\/p>\n Andre indikationer:<\/strong> Godartet prostatahyperplasi:<\/strong> start 1 mg at bedtime, titrate to 5-10 mg once daily over 2-4 weeks. Dose at bedtime indefinitely to minimise orthostatic effects. Symptom benefit typically clear by 4-6 weeks; if inadequate, switch to or add a prostate-selective alpha-1A blocker (tamsulosin) or a 5-alpha-reductase inhibitor (finasteride) for larger prostates (>40 g).<\/p>\n Administration:<\/strong> take once daily at bedtime. Food does not significantly affect absorption.<\/p>\n Overv\u00e5gningsplan:<\/strong><\/p>\n Oph\u00f8r:<\/strong> Ingen rebound-syndrom. Alfa-blokkere kan stoppes, men forvent en vis stigning i blodtrykket, hvis de bidrog v\u00e6sentligt til kontrollen. Genoptag med startdosis (ikke den tidlige vedligeholdelsesdosis), hvis genoptages efter en pause p\u00e5 mere end 1 uge \u2014 f\u00f8rste-dosis-f\u00e6nomenet vender tilbage.<\/p>\n Almindelige (>1%):<\/strong><\/p>\n Ikke almindelige, men klinisk vigtige:<\/strong><\/p>\n Graviditet:<\/strong> undg\u00e5s \u2014 begr\u00e6nsede graviditetsdata for alfa-blokkere. Skift til methyldopa, labetalol eller nifedipin ved graviditetsforh\u00f8jet blodtryk.<\/p>\n Amning:<\/strong> begr\u00e6nsede data; brug med forsigtighed. Skift hvor muligt til et middel med bedre ammeperiodedata (labetalol, nifedipin, enalapril).<\/p>\nHvorfor bestille fra MedsBase<\/h3>\n
What Is Hytrin?<\/h2>\n
How Terazosin Works<\/h2>\n
\n
Godkendte og evidensbaserede anvendelser<\/h2>\n
\n
Hytrin Dosage<\/h2>\n
\n
Practical Considerations for Hytrin<\/h2>\n
\n
Bivirkninger<\/h2>\n
\n
\n
Kontraindikationer<\/h2>\n
\n
L\u00e6gemiddelinteraktioner<\/h2>\n
\n
Where Hytrin Fits in the Antihypertensive Hierarchy<\/h2>\n